In this study, we further explore the therapeutic value of targeted disruption of the DOT1L recruitment by MLL-AF9 onco-fusion protein in AML and elucidate the role of this protein-protein interaction in non-leukemic hematopoiesis. Here, DOT1L is linked to acute myeloid leukemia.